Boston Early-Onset Chronic Obstructive Pulmonary Disease (COPD) Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01177618|
Recruitment Status : Recruiting
First Posted : August 9, 2010
Last Update Posted : July 8, 2020
|Condition or disease|
|Chronic Obstructive Pulmonary Disease|
Chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in the United States, affects millions of people around the world. COPD, which can include both emphysema and chronic bronchitis, affects the lungs making it very difficult to breathe. Cigarette smoking is the most common risk factor for developing COPD; however, only 15% to 20% of smokers develop COPD in their lifetimes. The onset of COPD also varies greatly from person to person; while some people do not develop respiratory symptoms until later in life, there are others who develop severe COPD at a very early age. Prior research has led to the discovery of the alpha-1 antitrypsin protein deficiency in association with COPD development. This discovery has generated further interest toward studying other genetic factors which may also affect an individual's likelihood of developing COPD. Therefore, the purpose of the Boston Early-Onset COPD study is to gain a better understanding of COPD risk factors in order to establish new possible methods of treatment for people affected by COPD.
For this study we are enrolling individuals affected with severe COPD (52 years old or younger with an FEV1 < 40%) and their family members. Each participant will attend one study visit that involves a respiratory questionnaire, a breathing test, and blood draw. This visit can be completed at the participant's home, in the hospital, or by long distance data collection (phone interview, local breathing tests, and local blood draw with mailed samples), whichever is preferred.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Genetic Epidemiology of Severe, Early-Onset Chronic Obstructive Pulmonary Disease|
|Study Start Date :||July 1994|
|Estimated Primary Completion Date :||July 2022|
|Estimated Study Completion Date :||July 2022|
Severe, early-onset COPD subjects that bring the family into the study
Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
- No Primary Outcome [ Time Frame: Single Visit for approximately two hours to collect study data and samples ]Since this is an observational study, there are no primary outcomes
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01177618
|Contact: Edwin K. Silverman, M.D., Ph.D.||email@example.com|
|United States, Massachusetts|
|Brigham and Women's Hospital||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: Edwin Silverman 617-525-0856 firstname.lastname@example.org|
|Contact: Gisselle Gonzalez 617-525-2128 email@example.com|
|Principal Investigator: Edwin K. Silverman, M.D., Ph.D.|
|Sub-Investigator: Dawn L. DeMeo, M.D.|
|Sub-Investigator: Craig P. Hersh, M.D.|
|Principal Investigator:||Edwin K. Silverman, M.D., Ph.D.||Brigham and Women's Hospital|